Skip to content
Redx Pharma logo — Biotech company focusing on the discovery and development of...

Redx Pharma

Biotech company focusing on the discovery and development of novel targeted medicines to treat cancer and fibrosis

Founded 2010 United Kingdom United Kingdom 39 employees Post-IPO Equity Total: $78.90M Biotechnology, Health Care +1

General Information

Company Name Redx Pharma
Founded Year 2010
Location United Kingdom United Kingdom
Founders / Decision Makers
Team member
Employees 39
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Business Model B2B, B2D
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Redx Pharma. To contact Redx Pharma, visit redxpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Redx Pharma compare?

A PDF of Redx Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Redx Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Redx Pharma

Founded in 2010, Redx Pharma is a clinical-stage biotechnology company headquartered in the United Kingdom. The company is dedicated to the discovery and development of novel, small molecule, targeted therapeutics for treating cancer and fibrotic diseases. Its strength lies in its team of world-class scientists located at Alderley Park, the UK's largest life science campus.

Redx Pharma's strategic focus is underscored by its lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), currently in a Phase 2 clinical trial for idiopathic pulmonary fibrosis. Additionally, their second candidate, RXC008, caters to fibrostenotic Crohn’s disease, initiating a Phase 1 trial in Q1 2024. The company's lead oncology product, the Porcupine inhibitor, zamaporvint (RXC004), has been in a Phase 2 program since November 2021.

The company last raised £35.00M through a Post-IPO Equity investment on 19 May 2022. Redx's robust background in medicinal chemistry and translational science positions it as a promising player in the biotechnology sector, particularly for investors interested in innovative cancer and fibrosis treatments.

Business keywords: Drug Discovery, Clinical Stage, Small Molecule Therapeutics, Cancer Treatment, Fibrotic Diseases, ROCK2 Inhibitor, Pulmonary Fibrosis, Crohn’s Disease, Porcupine Inhibitor, Oncology, Fibrosis, Translational Science, Medicinal Chemistry, Pharmaceutical Partnerships

Services & Products

Development of novel medicines
Clinical trials and research
Pharmaceutical partnerships
Scientific publications

Target Customers

Medical professionals Patients with fibrotic diseases Pharmaceutical partners Investors in biotechnology

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity £35.00M -
19 May 2022
Post IPO Equity £26.30M 2
Sofinnova Partners, Redmile Group
02 Mar 2020
Grant $1.00M 1
CARB-X
31 Mar 2017
Post IPO Equity Undisclosed 1
Seneca Partners
07 Mar 2017
Post IPO Equity £10.00M -
29 Mar 2016
Venture Round Undisclosed 1
Acceleris Capital
07 May 2013
Grant £4.70M 1
Regional Growth Fund
19 Oct 2012
Venture Round £1.90M 3
Northwest Regional Development Agency, Jon Moulton +1
12 Oct 2010

Redx Pharma Alternatives & Competitors

View All Alternatives
Redx Pharma vs

Boldly pursuing development of transformational medicines that may restore hope for patients with in...

Series C
52 employees
Biotechnology, Health Care
Redx Pharma vs

Targeting Metabolic Reprogramming in Fibrosis and Oncology

7 employees
Biopharma, Biotechnology
Redx Pharma vs

A precision oncology company focused on small molecule therapies optimized to target key driver mech...

Series A
52 employees
Biotechnology, Health Care

FAQ About Redx Pharma

Biotech company focusing on the discovery and development of novel targeted medicines to treat cancer and fibrosis
Redx Pharma was founded in 2010.
Redx Pharma is headquartered in United Kingdom.
Redx Pharma operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Drug Discovery, Clinical Stage, Small Molecule Therapeutics and Cancer Treatment. Its customers include Medical professionals, Patients with fibrotic diseases and Pharmaceutical partners.
Redx Pharma has a B2B and B2D business model. Its revenue comes from Licensing, Performance Based and Product Sales.
Redx Pharma has approximately 39 employees.
Redx Pharma has completed 8 funding rounds, raising a total of $78.90M. The latest funding stage is Post-IPO Equity.
Redx Pharma offers: Development of novel medicines, Clinical trials and research, Pharmaceutical partnerships, Scientific publications.
Top alternatives and competitors to Redx Pharma include Endeavor BioMedicines, ImmunoMet Therapeutics, Inc., Synnovation Therapeutics, CV6 Therapeutics, (NI) Ltd., Agomab. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Redx Pharma and Endeavor BioMedicines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Redx Pharma, https://bouncewatch.com/company/redx-pharma, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout